TRLS-11. A PHASE 1 STUDY OF SAVOLITINIB IN RECURRENT, PROGRESSIVE, OR REFRACTORY MEDULLOBLASTOMA, HIGH-GRADE GLIOMA, DIFFUSE INTRINSIC PONTINE GLIOMA, AND CENTRAL NERVOUS SYSTEM (CNS) TUMORS HARBORING MET ABERRATIONS: A PEDIATRIC BRAIN TUMOR CONSORTIUM TRIAL

Aberrant mesenchymal epithelial transition receptor (MET) activation leads to neoplasia, promotes invasive tumor growth, angiogenesis, and metastasis. Deregulation of MET signaling pathway is frequently observed in pediatric CNS tumors making MET inhibition a potential therapeutic target in this pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Salloum, Ralph, Huang, Jie, Stewart, Clinton F, Fuller, Christine, Smolarek, Teresa, Lenzen, Alicia, Waanders, Angela J, Baxter, Patiricia, Lindsay, Holly, Robison, Nathan, Pillay-Smiley, Natasha, Partap, Sonia, Fangusaro, Jason, Onar-Thomas, Arzu, Fouladi, Maryam, Dunkel, Ira J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Final Category: Translational Therapeutics/Clinical Trials - TRLS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260066/
http://dx.doi.org/10.1093/neuonc/noad073.314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260066/
http://dx.doi.org/10.1093/neuonc/noad073.314

Ejemplares similares